[go: up one dir, main page]

NO20083183L - Fast farmasoytisk sammensetning inneholdende irbesartan - Google Patents

Fast farmasoytisk sammensetning inneholdende irbesartan

Info

Publication number
NO20083183L
NO20083183L NO20083183A NO20083183A NO20083183L NO 20083183 L NO20083183 L NO 20083183L NO 20083183 A NO20083183 A NO 20083183A NO 20083183 A NO20083183 A NO 20083183A NO 20083183 L NO20083183 L NO 20083183L
Authority
NO
Norway
Prior art keywords
solid pharmaceutical
pharmaceutical composition
composition containing
irbesartan
containing irbesartan
Prior art date
Application number
NO20083183A
Other languages
English (en)
Inventor
Renata Jakse
Miha Vrbinc
Silvo Zupancic
Franci Bevec
Original Assignee
Krka Dd Novo Mesto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krka Dd Novo Mesto filed Critical Krka Dd Novo Mesto
Publication of NO20083183L publication Critical patent/NO20083183L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Den foreliggende oppfinnelsen angår fortrinnsvis faste farmasøytiske formuleringer frie for overflateaktivt middel som omfatter, som en aktiv ingrediens, minst én av irbesartan og farmasøytisk akseptable salter derav og minst ett desintegrerende middel. Fortrinnsvis omfatter den aktive ingrediensen irbesartanhydroklorid. I tillegg er den foreliggende oppfinnelsen rettet mot en fremgangsmåte til fremstilling av slike formuleringer inkludert en våtgranuleringsprosess (A) og en direkte granuleringsprosess (B).
NO20083183A 2006-01-09 2008-07-17 Fast farmasoytisk sammensetning inneholdende irbesartan NO20083183L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06000329A EP1806130B1 (en) 2006-01-09 2006-01-09 Solid pharmaceutical composition comprising irbesartan
PCT/EP2007/000074 WO2007080074A1 (en) 2006-01-09 2007-01-05 Solid pharmaceutical composition comprising irbesartan

Publications (1)

Publication Number Publication Date
NO20083183L true NO20083183L (no) 2008-09-26

Family

ID=35744710

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083183A NO20083183L (no) 2006-01-09 2008-07-17 Fast farmasoytisk sammensetning inneholdende irbesartan

Country Status (15)

Country Link
US (1) US20110045097A1 (no)
EP (2) EP1806130B1 (no)
CN (1) CN101370484B (no)
AT (1) ATE462414T1 (no)
CA (1) CA2636663A1 (no)
DE (1) DE602006013261D1 (no)
EA (1) EA016579B1 (no)
ES (1) ES2340701T3 (no)
HR (1) HRP20100216T1 (no)
NO (1) NO20083183L (no)
PL (1) PL1806130T3 (no)
PT (1) PT1806130E (no)
SI (1) SI1806130T1 (no)
UA (1) UA95274C2 (no)
WO (1) WO2007080074A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006006588A1 (de) 2006-02-13 2007-08-16 Ratiopharm Gmbh Schnell freisetzende Irbesartan-haltige pharmazeutische Zusammensetzung
CA2682929A1 (en) * 2007-04-17 2008-10-23 Ratiopharm Gmbh Pharmaceutical compositions comprising irbesartan
EP2065035B1 (en) 2007-11-28 2010-07-21 Laboratorios Lesvi, S.L. Pharmaceutical formulations containing irbesartan
WO2011141783A2 (en) 2010-04-13 2011-11-17 Micro Labs Limited Pharmaceutical composition comprising irbesartan
CN101912390A (zh) * 2010-08-08 2010-12-15 浙江华海药业股份有限公司 含厄贝沙坦的药用组合物
CN103191076B (zh) * 2013-04-27 2016-08-17 吕丕平 一种厄贝沙坦片剂的制备方法
JP6445923B2 (ja) * 2015-04-22 2018-12-26 ダイト株式会社 イルベサルタン含有錠剤の調製方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
NZ237476A (en) 1990-03-20 1994-01-26 Sanofi Sa N-substituted heterocyclic compounds and pharmaceutical compositions.
US5541209A (en) * 1994-08-22 1996-07-30 Bristol-Myers Squibb Company Method of treating or preventing cardiac arrhythmia employing an N-substituted heterocyclic derivative
FR2725987B1 (fr) 1994-10-19 1997-01-10 Sanofi Sa Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
FR2780403B3 (fr) * 1998-06-24 2000-07-21 Sanofi Sa Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
TWI324074B (en) * 2001-10-09 2010-05-01 Bristol Myers Squibb Co Flashmelt oral dosage formulation
US20050176793A1 (en) 2001-12-10 2005-08-11 Reddy Reguri B. Amorphous form of 2-n-butyl-3-((2-(1h-tetrazol-5-yl)([1,1'-biphenyl)-4-yl)methyl)-1, 3-diazaspiro(4,4')non-1-en-4-one
PT1546135E (pt) 2002-07-16 2006-12-29 Teva Pharma Nova síntese de irbesartan
TR200301553A1 (tr) * 2003-09-18 2005-10-21 Nobel �La� Sanay�� Ve T�Caret A.�. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
PL1750862T3 (pl) * 2004-06-04 2011-06-30 Teva Pharma Kompozycja farmaceutyczna zawierająca irbesartan
WO2006013545A1 (en) * 2004-07-28 2006-02-09 Ranbaxy Laboratories Limited Pharmaceutical compositions of irbesartan
SI21849A (sl) * 2004-07-29 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Priprava hidrokloridnih soli tetrazolskega derivata
GB2419592A (en) * 2004-10-26 2006-05-03 Cipla Ltd Process for the preparation of irbesartan hydrochloride
US20060160871A1 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
WO2006067601A1 (en) * 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of irbesartan and hydrochlorothiazide and processes for their preparation

Also Published As

Publication number Publication date
CN101370484B (zh) 2011-06-01
PT1806130E (pt) 2010-05-11
UA95274C2 (ru) 2011-07-25
WO2007080074A1 (en) 2007-07-19
PL1806130T3 (pl) 2010-08-31
ATE462414T1 (de) 2010-04-15
DE602006013261D1 (de) 2010-05-12
ES2340701T3 (es) 2010-06-08
CA2636663A1 (en) 2007-07-19
EA016579B1 (ru) 2012-06-29
CN101370484A (zh) 2009-02-18
HRP20100216T1 (hr) 2010-05-31
EP1806130A1 (en) 2007-07-11
EP1806130B1 (en) 2010-03-31
EP1981485A1 (en) 2008-10-22
EA200801634A1 (ru) 2008-10-30
US20110045097A1 (en) 2011-02-24
SI1806130T1 (sl) 2010-06-30
EP1981485B1 (en) 2014-10-08

Similar Documents

Publication Publication Date Title
PT2043600T (pt) Formulações farmacêuticas para a libertação prolongada de princípio(s) ativo(s), assim como suas aplicações, nomeadamente terapêuticas
NO20083183L (no) Fast farmasoytisk sammensetning inneholdende irbesartan
NO20043367L (no) Oralt farmasoytisk preparat
WO2006082523A3 (en) Pharmaceutical sustained release composition of metformin
HRP20160327T1 (hr) Čvrsti dozirni oblici fentanila s poboljšanom bukalnom apsorpcijom
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
DK2451445T3 (da) Fremgangsmåde til at tørre bibw2992, dets salte og faste farmaceutiske formuleringer omfattende denne aktive ingrediens
MX2007012443A (es) Formulaciones farmaceuticas orales que comprenden acido fenofibrico y/o sus sales.
UA95199C2 (en) Aqueous formulation of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
ECSP088560A (es) Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido
EP2178869A4 (en) INDOL COMPOUNDS AS AN INHIBITORS OF CELL NECROSIS
EA200801184A1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
CY1113759T1 (el) Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
DK1820506T3 (da) Dipyridamol-formuleringer med forlænget frigivelse og fremgangsmåde til fremstilling heraf
DE602005027540D1 (de) Feste formulierungen von ospemifen
MA32964B1 (fr) Formulation a effet retard d'octreotide avec niveau d'exposition constamment eleves
DK2197428T3 (da) Forbedret farmaceutisk sammensætning, der indeholder et pyrrolidon-antikrampemiddel, og fremgangsmåde til fremstilling heraf
ATE473212T1 (de) Hiv-inhibierende 2-(4-cyanophenyl)-6- hydroxylaminopyrimidine
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
ATE479427T1 (de) Pharmazeutische zusammensetzung mit candesartan- cilexetil
TW200744583A (en) Statin stabilizing dosage formulations
CY1114306T1 (el) Νεα συνθεση για τη θεραπευτικη αντιμετωπιση της ιδιοπαθους θρομβοκυτταραιμιας
EP2077111A4 (en) ANTIDEPRESSANT

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application